ROMO-DISSERTATION-2016.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

ROMO-DISSERTATION-2016.Pdf Copyright by Anthony James Romo 2016 The Dissertation Committee for Anthony James Romo Certifies that this is the approved version of the following dissertation: Discovery of the Amipurimycin and Miharamycins Biosynthetic Gene Clusters and Insight into the Biosynthesis of Nogalamycin Committee: Hung-wen (Ben) Liu, Supervisor Walter L. Fast Adrian T. Keatinge-Clay Sean M. Kerwin Christian P. Whitman Discovery of the Amipurimycin and Miharamycins Biosynthetic Gene Clusters and Insight into the Biosynthesis of Nogalamycin by Anthony James Romo, Pharm.D. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin May 2016 Dedication I would like to dedicate this work to my amazingly talented wife, Dr. Dawn Kim- Romo, and our beautiful son, Julian Romo. Thank you for encouraging me to continue when I wanted to quit and for giving me the inspiration to reach farther than my grasp. "O sol che sani ogne vista turbata, tu mi contenti sì quando tu solvi, che, non men che saver, dubbiar m'aggrata.” (Dante, Inferno, 11.91-93) Acknowledgements First of all, I want to thank God for my wife and son and for the strength to get through my graduate studies, for, though it is often said at this point in a graduate student’s life, there were times when I really could never imagine finishing graduate school! I would be completely and unforgivably remiss if I did not thank the people who have helped shape my experience. I thank Dr. Zhiwen (Jonathan) Zhang for giving me my first experience in medicinal chemistry research and Dr. Gabby Moreno-Thibodeaux for being my first mentor. Next, I would like to thank Dr. Hung-wen (Ben) Liu for allowing me to work in and ultimately study in his lab, and Dr. Yung-nan Liu for greatly facilitating my progress. Not only was Dr. Liu a knowledgeable and thoughtful advisor, but my time in his lab allowed me to interact with a vibrant and enthusiastic group of graduate students and postdocs, some of whom have made a lifelong impression on me. I would like to specifically thank Dr. Yasushi Ogasawara for giving me the set of skills that were instrumental to my work; Aoshu Zhong for being an apt protégé and skillful teacher; Geng-Min Lin for his patient guidance and encouragement, as well as for continuing my work; Dr. Chia-I Lin for her advice and expertise which often helped me to think more deeply about my results; and finally, Dr. Mark Ruszczycky for telling me to stop “thinking like a first year graduate student” and for being one of the most thorough editors I have ever met. I will never forget my time in the Liu Lab, and I am glad to join the brilliant alumni who have studied with Dr. Liu. Finally, I would like to thank my committee members for their patience and commitment to this endeavor. v Discovery of the Amipurimycin and Miharamycins Biosynthetic Gene Clusters and Insight into the Biosynthesis of Nogalamycin Anthony James Romo, Ph.D. The University of Texas at Austin, 2016 Supervisor: Hung-wen (Ben) Liu Advancements in our ability to obtain high quality bacterial whole genome sequences have increased the rate natural product biosynthetic gene clusters are identified, but these projects require computational methods for gene annotation which are limited by their reliance on comparison to previously annotated genes. Thus, even in a well-defined cluster with a known product it may be difficult to predict how structural characteristics arise if they have no known precedent. Without further work, such limitations will continue to impede the utility of sequenced bacterial genomes. Biosyntheses of the peptidyl nucleoside antibiotics and atypical anthracyclines like nogalamycin are topics which exemplify these challenges. The peptidyl nucleoside antibiotics (PNAs) are a structurally complex group of natural products with diverse biological activities which could be useful for the development of novel antimicrobials. Amipurimycin and the miharamycins are remarkably similar PNAs elaborated by the bacteria Streptomyces miharaensis ATCC 19440 and Streptomyces novoguineensis CBS 199.78, respectively. Their dissimilarity to other well-characterized groups of antibiotics has presented a challenge to the study of their unique structural features. Herein, we describe the identification of the amipurimycin and miharamycins biosynthetic gene clusters though a comparative genomics approach. vi Besides providing insight into the biosynthesis of the rare amino acids adorning these PNA, our analysis revealed a plausible biosynthetic route to the unique 2-aminopurine nucleobase and suggests the core saccharides are generated by a polyketide synthase. The anthracyclines are a mainstay of chemotherapy, but their use is limited by fatal cardiotoxicity and tumor resistance. The structures of the anthracyclines are sensitive to modification, as even small changes can ablate their biological activity. Nevertheless, the diversification of anthracyclines through semi- or total syntheses is an ongoing effort. Nogalamycin is rare amongst the anthracyclines because of its extended ring system and unusual glycosylation pattern. It is hoped an understanding of the biosynthesis of nogalamycin could allow the incorporation of its uncommon structural features into other anthracyclines to develop novel compounds with improved actitivty. Towards this end, we investigated the biosynthesis of the amino sugar found in nogalamycin, nogalamine, to clarify ambiguous steps in the reported biosynthetic pathway for this sugar. vii Table of Contents List of Tables ....................................................................................................... xiii List of Figures ...................................................................................................... xiv Chapter 1: Biosynthesis of The Peptidyl Nucleoside Antibiotics and Glycosylation of Anthracyclines, Under-Explored Topics in the Study of Natural Products ....1 1.1. INTRODUCTION ........................................................................................1 1.2. BIOSYNTHESIS OF THE PEPTIDYL NUCLEOSIDE ANTIBIOTICS ....3 1.2.1. Introduction ......................................................................................3 1.2.2. Amino Acid Attachment ..................................................................5 1.2.2.1. ATP-dependent Peptide Bond Formation ....................................7 1.2.2.1.1. ATP-grasp Ligases ...............................................................7 Blasticidin S ..................................................................................8 Polyoxins and Nikkomycins .........................................................9 Albomycins .................................................................................11 A201A .........................................................................................13 1.2.2.1.2. Non-Ribosomal Peptide Synthetases ..................................14 Muraymycins ..............................................................................15 Pacidamycins ..............................................................................17 Streptothricins .............................................................................20 1.2.2.2. ATP-independent Peptide Bond Formation ...............................23 1.2.2.2.1. N-acylation .........................................................................23 Amicetins ....................................................................................23 Gougerotin ..................................................................................25 1.2.2.2.2. Miscellaneous .....................................................................27 Pacidamycins ..............................................................................27 A-503083 ....................................................................................28 Muraymycins ..............................................................................29 1.2.2.3. Unknown Mechanism ................................................................30 Blasticidin S and Mildiomycin ...................................................30 viii Puromycin ...................................................................................31 1.2.3. Core Saccharide Origin: Beyond Hexoses Versus Pentoses ..........32 1.2.3.1. Incidental....................................................................................32 Puromycin and A201A ...............................................................33 Pacidamycins ..............................................................................34 1.2.3.2. Intact ..........................................................................................36 Blasticidin S, Arginomycin, and Gougerotin ..............................36 Streptothricins .............................................................................40 Amicetins ....................................................................................42 1.2.3.3. Built-up ......................................................................................43 Polyoxins and Nikkomycins .......................................................43 Mildiomycin ................................................................................44 Albomycins .................................................................................45 A-503083s ...................................................................................47
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,822,539 B2 Jensen (45) Date of Patent: Sep
    USOO8822.539B2 (12) United States Patent (10) Patent No.: US 8,822,539 B2 Jensen (45) Date of Patent: Sep. 2, 2014 (54) COMBINATION THERAPIES: INHIBITORS Bialer et al., “Progress report on new antiepileptic drugs: a Summary OF GABA TRANSAMINASE AND NKCC1 of the Seventh Eilat Conference (EILATVII).” Epilepsy Res., 61:1- 48, 2004 (Abstract only). (75) Inventor: Frances E. Jensen, Boston, MA (US) Clift and Silverman, “Synthesis and Evaluation of Novel Aromatic Substrates and Competitive Inhibitors of GABA Aminotransferase.” (73) Assignee: Children's Medical Center Bioorg. Med. Chem. Left., 18:3122-3125, 2008. Crewther et al., “Potassium Channel and NKCC Cotransporter Corporation, Boston, MA (US) Involvement in Ocular Refractive Control Mechanisms. PlosOne, 3:e2839, 2008. (*) Notice: Subject to any disclaimer, the term of this Cubells et al., “In vivo action of enzyme-activated irreversible inhibi patent is extended or adjusted under 35 tors of glutamic acid decarboxylase and gamma-aminobutyric acid U.S.C. 154(b) by 149 days. transaminase in retina vs. brain.” J. Pharmacol. Exp. Ther. 238:508 514, 1986 (Abstract only). (21) Appl. No.: 13/069,311 Duboc et al., “Vigabatrin, the GABA-transaminase inhibitor, dam ages cone photoreceptors in rats.” Ann. Neurol. 55:695-705, 2004 (22) Filed: Mar 22, 2011 (Abstract only). Dzhala et al., “Bumetanide enhances phenobarbital efficacy in a (65) Prior Publication Data neonatal seizure model.” Ann. Neurol. 63:222-235, 2008 (Abstract US 2011/0237554 A1 Sep. 29, 2011 only). Dzhala et al., “NKCC1 transporter facilitates seizures in the devel oping brain.” Nature Med., 11:1205-1213, 2005 (Abstract only). Follett et al., “Glutamate Receptor-Mediated Oligodendrocyte Tox Related U.S.
    [Show full text]
  • The Syntheses of Β-Lactam Antibiotics from 3-Formylcephalosporins As the Key-Intermediates
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/19082 Please be advised that this information was generated on 2021-10-03 and may be subject to change. The Syntheses of β-Lactam Antibiotics from 3-Formylcephalosporins as the Key-intermediates Een wetenschappelijke proeve op het gebied van de Natuurwetenschappen, Wiskunde en Informatica Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen, volgens besluit van het College van Decanen in het openbaar te verdedigen op woensdag 6 februari 2002 des namiddags om 1.30 uur precies door Rolf Keltjens Geboren op 9 april 1972 te Horst Promotor Prof. dr. B. Zwanenburg Copromotor Dr. A.J.H. Klunder Manuscriptcommissie Dr. E. de Vroom (DSM Anti-Infectives, Delft) Dr. J. Verweij (voorheen DSM Anti-Infectives, Delft) Prof. dr. ir. J.C.M. van Hest The research described in this PhD thesis was part of the Cluster Project "Fine- Chemistry" and was financially supported by DSM (Geleen, The Netherlands) and the Dutch Ministry of Economical Affairs (Senter). ISBN 90-9015389-6 Omslag: Penicillium chrysogenum (copyright DSM N.V.) "Experiment is the sole interpreter of the artifices of Nature" Leonardo da Vinci (1452-1519) Aan mijn ouders Paranimfen René Gieling Sander Hornes VOORWOORD Als het manuscript nagenoeg gereed is en het geheel klaar is voor verzending naar de drukker, is het ook de hoogste tijd om de mensen met wie je vier jaar lang intensief hebt samengewerkt te bedanken.
    [Show full text]
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
    [Show full text]
  • Contribution to Physico-Chemical Studies of Squalenoylated Nanomedicines for Cancer Treatment Julie Mougin
    Contribution to physico-chemical studies of squalenoylated nanomedicines for cancer treatment Julie Mougin To cite this version: Julie Mougin. Contribution to physico-chemical studies of squalenoylated nanomedicines for cancer treatment. Theoretical and/or physical chemistry. Université Paris-Saclay, 2020. English. NNT : 2020UPASS038. tel-02885220 HAL Id: tel-02885220 https://tel.archives-ouvertes.fr/tel-02885220 Submitted on 30 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Contribution to physico-chemical studies of squalenoylated nanomedicines for cancer treatment Thèse de doctorat de l'université Paris-Saclay École doctorale n° 569, Innovation thérapeutique : du fondamental à l’appliqué (ITFA) Spécialité de doctorat : Pharmacotechnie et Biopharmacie Unité de recherche : Université Paris-Saclay, CNRS, Institut Galien Paris Sud, 92296, Châtenay-Malabry, France Référent : Faculté de Pharmacie Thèse présentée et soutenue à Châtenay-Malabry, le 28/02/2020, par Julie MOUGIN Composition du Jury Elias FATTAL Président Professeur, Université
    [Show full text]
  • Comparison of the Interaction of Doxorubicin, Daunorubicin, Idarubicin and Idarubicinol with Large Unilamellar Vesicles Circular Dichroism Study
    Biochimica et Biophysica Acta 1370Ž. 1998 31±40 View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles Circular dichroism study Laurence Gallois, Marina Fiallo, Arlette Garnier-Suillerot ) Laboratoire de Physicochimie BiomoleculaireÂÂ et Cellulaire() URA CNRS 2056 , UniÕersite Paris Nord, 74, rue Marcel Cachin, 93017 Bobigny Cedex, France Received 6 August 1997; revised 25 September 1997; accepted 2 October 1997 Abstract Doxorubicin, daunorubicin and other anthracycline antibiotics constitute one of the most important groups of drugs used today in cancer chemotherapy. The details of the drug interactions with membranes are of particular importance in the understanding of their kinetics of passive diffusion through the membrane which is itself basic in the context of multidrug resistanceŽ. MDR of cancer cells. Anthracyclines are amphiphilic molecules possessing dihydroxyanthraquinone ring system which is neutral under the physiological conditions. Their lipophilicity depends on the substituents. The amino sugar moiety bears the positive electrostatic charge localised at the protonated amino nitrogen. The four anthracyclines used in this study doxorubicin, daunorubicin, idarubicin and idarubicinolŽ. an idarubicin metabolite readily formed inside the cells have the same amino sugar moiety, daunosamine, with pKa of 8.4. Thus, all drugs studied will exhibit very similar electrostatic interactions with membranes, while the major differences in overall drug-membrane behaviour will result from their hydrophobic features. Circular dichroismŽ. CD spectroscopy was used to understand more precisely the conformational aspects of the drug±membrane systems. Large unilamellar vesiclesŽ. LUV consisting of phosphatidylcholine, phosphatidic acidŽ.
    [Show full text]
  • Light and Electron Microscope Evidence for Involvement of Neuroglia (Cerebellum/Cyclic AMP/Y-Aminobutyric Acid/Harmaline/Diazepam) V
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 3, pp, 1485-1488, March 1979 Neurobiology Immunocytochemical localization of cyclic GMP: Light and electron microscope evidence for involvement of neuroglia (cerebellum/cyclic AMP/y-aminobutyric acid/harmaline/diazepam) V. CHAN-PALAY* AND S. L. PALAYt Departments of *Neurobiology and tAnatomy, Harvard Medical School, Boston, Massachusetts 02115 Contributed by Sanford L. Palay, December 7, 1978 ABSTRACT Guanosine 3',5'-cyclic monophosphate (cGMP) presents cytopharmacological evidence from immunocyto- immunoreactivity in the rat's cerebellum was studied with light chemistry for the cellular and subcellular location of cGMP in and electron microscopy by the indirect fluorescence method some cerebellar neurons and particularly in neuroglial cells. and the peroxidase-antiperoxidase method. Labeled cells in- cluded neuroglial cells in the cerebellar cortex, white matter, and deep nuclei; some stellate and basket cells in the cortex; and MATERIALS AND METHODS some large neurons in the deep nuclei. No evidence was found Adult 200-300 g Sprague-Dawley rats, the indirect immu- for sagittal microzonation in the cGMP distribution. In the la- nofluorescence method (11), and the peroxidase-antiperoxidase beled cells, cGMP immunoreactive sites were localized to sur- face membranes, organelles, and the cytoplasmic matrix. (PAP) method (12) for light and electron microscopy were used. Specificity was indicated by the same pattern of labeling after Rabbit antisera were raised against the 2'-O-succinyl derivative treatment with cGMP immunoglobulin that had been adsorbed of cGMP or cAMP conjugated to limpet hemocyanin (13). More with adenosine 3',5'-cyclic monophosphate (cAMP) and by the than 50% of 2'-O-succinyl-cGMP ([125I]iodotyrosine methyl failure to label after treatment with normal rabbit sera or with ester derivative) or 2'-O-succinyl-cAMP ([1251]iodotyrosine cGMP immunoglobulin that had been adsorbed with 1 mM methyl ester derivative) (<0.01 pmol) was bound at a serum cGMP.
    [Show full text]
  • Increase in the Bmax of Y-Aminobutyric Acid-A Recognition Sites in Brain Regions of Mice Receiving Diazepam
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 2247-2251, April 1984 Neurobiology Increase in the Bmax of y-aminobutyric acid-A recognition sites in brain regions of mice receiving diazepam (muscimol/-aminobutyric acid receptors/benzodiazepine receptors/locomotor activity) P. FERRERO, A. GuIDOTTI, AND E. COSTA* Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, DC 20032 Contributed by E. Costa, December 12, 1983 ABSTRACT y-Aminobutyric acid (GABA) receptors were MATERIALS AND METHODS characterized in vivo by studying ex vivo the binding of [3H]Muscimol (New England Nuclear) labeled on the meth- [3H]muscimol to cerebellum, cortex, hippocampus, and cor- ylene side-chain (specific activity, 29.4 Ci/mmol; 1 Ci = 37 pus striatum of mice receiving intravenous injections of tracer GBq) was injected into the tail vein of female mice (20-25 g). doses of high-specific-activity (-30 Ci/mmol) [3H]muscimol. Routinely, the dose of [3H]muscimol injected was 5 uCi per This ligand binds with high affinity (apparent Kd, 2-3 x 10-9 20 g of body weight in 0.2 ml of saline. This radiolabeled M) to a single population of binding sites (apparent Bmax, 250- ligand dose was administered either alone or with various 180 fmol per 10 mg of protein). Pharmacological studies using doses of unlabeled muscimol. In some experiments, drugs that selectively bind to GABAA or GABAB receptors [3H]muscimol was injected into cerebral ventricles through a suggest that [3H]muscimol specifically labels a GABAA recog- polyethylene cannula chronically implanted (13). The dissec- nition site. Moreover, diazepam (1.5 ,umol/kg, i.p.) increases tion of the different brain areas (cerebellum, cortex, stria- the Bmax but fails to change the affinity of [3Hlmuscimol bind- tum, and hippocampus) was carried out on a chilled (00C) ing to different brain areas.
    [Show full text]
  • Multifunctional Colloidal-Based Nanoparticles for Cancer Treatment Bioengineering and Nanosystems
    Multifunctional colloidal-based nanoparticles for cancer treatment Rita Falcão Baptista Ribeiro Mendes Thesis to obtain the Master of Science Degree in Bioengineering and Nanosystems Supervisors: Doctor Marlene Susana Dionísio Lúcio Doctor Susana Isabel Pinheiro Cardoso de Freitas Examination Committee Chairperson: Doctor Gabriel António Amaro Monteiro Supervisor: Doctor Marlene Susana Dionísio Lúcio Members of the Committee: Doctor Maria Elisabete Cunha Dias Real Oliveira May 2017 Acknowledgments First of all I would like to thank to the college institutions where I fortunately had the opportunity to learn, grow and enrich myself during all my academic life, Instituto Superior Técnico (IST) and Universidade do Minho (UM). I would like to thank to Doctor Maria Elisabete Cunha Dias Real Oliveira the opportunity that gave me by accepting my request of working in the UM research team from the very first moment and all the concern and human support along the entire year. The present work would not be possible without all the availability, kindness and care that was always given to me during all the period of works. Secondly, I have to write a special word to my supervisor Doctor Marlene Susana Dionísio Lúcio, which despite the amount of work within hands, always had a time to support me and teach me with the major patience and commitment. The contagious passion for the scientific world that was constantly present in every single explanation was one of the most crucial aspects for the success of this work and for making me grow as a scientist and as a human being. I would always have to thank all the incredible technical and human support that was given to me all the time.
    [Show full text]
  • Pharmacological Studies on a Locust Neuromuscular Preparation
    J. Exp. Biol. (1974). 6i, 421-442 421 *&ith 2 figures in Great Britain PHARMACOLOGICAL STUDIES ON A LOCUST NEUROMUSCULAR PREPARATION BY A. N. CLEMENTS AND T. E. MAY Woodstock Research Centre, Shell Research Limited, Sittingbourne, Kent {Received 13 March 1974) SUMMARY 1. The structure-activity relationships of agonists of the locust excitatory neuromuscular synapse have been reinvestigated, paying particular attention to the purity of compounds, and to the characteristics and repeatability of the muscle response. The concentrations of compounds required to stimu- late contractions of the retractor unguis muscle equal in force to the neurally evoked contractions provided a measure of the relative potencies. 2. Seven amino acids were capable of stimulating twitch contractions, glutamic acid being the most active, the others being analogues or derivatives of glutamic or aspartic acid. Aspartic acid itself had no excitatory activity. 3. Excitatory activity requires possession of two acidic groups, separated by two or three carbon atoms, and an amino group a to a carboxyl. An L-configuration appears essential. The w-acidic group may be a carboxyl, sulphinyl or sulphonyl group. Substitution of any of the functional groups generally causes total loss of excitatory activity, but an exception is found in kainic acid in which the nitrogen atom forms part of a ring. 4. The investigation of a wide variety of compounds revealed neuro- muscular blocking activity among isoxazoles, hydroxylamines, indolealkyl- amines, /?-carbolines, phenazines and phenothiazines. No specific antagonist of the locust glutamate receptor was found, but synaptic blocking agents of moderately high activity are reported. INTRODUCTION The study of arthropod neuromuscular physiology has been impeded by the lack of an antagonist which can be used to block excitatory synaptic transmission by a specific postsynaptic effect.
    [Show full text]
  • Toxicol Rev 2004; 23 (1): 21-31 GHB SYMPOSIUM 1176-2551/04/0001-0021/$31.00/0
    Toxicol Rev 2004; 23 (1): 21-31 GHB SYMPOSIUM 1176-2551/04/0001-0021/$31.00/0 2004 Adis Data Information BV. All rights reserved. γ-Butyrolactone and 1,4-Butanediol Abused Analogues of γ-Hydroxybutyrate Robert B. Palmer1,2 1 Toxicology Associates, Prof LLC, Denver, Colorado, USA 2 Rocky Mountain Poison & Drug Center, Denver, Colorado, USA Contents Abstract ................................................................................................................21 1. Clinical Effects .......................................................................................................23 2. Diagnosis and Management ..........................................................................................25 3. Withdrawal ..........................................................................................................26 4. Conclusion ..........................................................................................................29 Abstract γ-Hydroxybutyrate (GHB) is a GABA-active CNS depressant, commonly used as a drug of abuse. In the early 1990s, the US Drug Enforcement Administration (DEA) warned against the use of GHB and restricted its sale. This diminished availability of GHB caused a shift toward GHB analogues such as γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) as precursors and surrogates. Both GBL and 1,4-BD are metabolically converted to GHB. Furthermore, GBL is commonly used as a starting material for chemical conversion to GHB. As such, the clinical presentation and management of GBL and 1,4-BD
    [Show full text]
  • Safety Review of Gamma-Aminobutyric Acid (GABA)
    nutrients Review United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA) Hellen A. Oketch-Rabah 1,*, Emily F. Madden 1, Amy L. Roe 2 and Joseph M. Betz 3 1 U.S. Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, USA; [email protected] 2 The Procter & Gamble Company, Cincinnati, OH 45202, USA; [email protected] 3 Office of Dietary Supplements, National Institutes of Health, Bethesda, MD 20892, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-301-230-3249 Abstract: Gamma-amino butyric acid (GABA) is marketed in the U.S. as a dietary supplement. USP conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as a natural constituent of fermented milk or soy matrices. Data showed no serious adverse events associated with GABA at intakes up to 18 g/d for 4 days and in longer studies at intakes of 120 mg/d for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (<10% change). No studies were available on effects of GABA during pregnancy and lactation, and no case reports or spontaneous adverse events associated with GABA were found. Chronic administration of GABA to rats and dogs at doses up to 1 g/kg/day showed no signs of toxicity. Because some studies showed that GABA was associated with decreases Citation: Oketch-Rabah, H.A.; in blood pressure, it is conceivable that concurrent use of GABA with anti-hypertensive medications Madden, E.F.; Roe, A.L.; Betz, J.M.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,040,552 B2 Arnelle Et Al
    US009040552B2 (12) United States Patent (10) Patent No.: US 9,040,552 B2 Arnelle et al. (45) Date of Patent: May 26, 2015 (54) SELECTIVE OPIOID COMPOUNDS Cancer online, retrieved on Jul. 6, 2007. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>.* (71) Applicant: Alkermes, Inc. Cancer online, retrieved on Jul. 6, 2007. Retrieved from the internet, URL: http://en.wikipedia.org.wiki|Cancer.* (72) Inventors: Derrick Arnelle, Arlington, MA (US); Irritable Bowel Syndrome online). Retrieved on Nov. 4, 2014 from Daniel Deaver, Franklin, MA (US); the internet. URL http://digestive.niddk.nih.gov/ddiseases/pubs/ Reginald L. Dean, III, Boxborough, bSt. MA (US); Mark Todtenkopf, Franklin, MA (US) * cited by examiner (73) Assignee: Alkermes, Inc., Waltham, MA (US) Primary Examiner — Shawquia Jackson *) Notice: Subject to anyy disclaimer, the term of this (74) Attorney, Agent, or Firm — Elmore Patent Law Group, patent is extended or adjusted under 35 U.S.C. 154(b) by 97 days. P.C.; Roy P. Issac; Carolyn S. Elmore (21) Appl. No.: 13/693,662 (57) ABSTRACT (22) Filed: Dec. 4, 2012 The present invention relates to compounds of Formula I or II, (65) Prior Publication Data or pharmaceutically acceptable salts, esters, or prodrugs US 2014/OOO5215A1 Jan. 2, 2014 thereof: Related U.S. Application Data (62) Division of application No. 12/371,334, filed on Feb. (I) 13, 2009, now Pat. No. 8,354,534. (60) Provisional application No. 61/028,780, filed on Feb. 14, 2008, provisional application No. 61/087,295, filed on Aug. 8, 2008. (51) Int.
    [Show full text]